Predictors of non-alcoholic fatty liver disease in children

Menglong Li1, Wen Shu1, Jiawulan Zunong1

  • 1Department of Child, Adolescent Health and Maternal Care, School of Public Health, Capital Medical University, Beijing, China.

Pediatric Research
|September 28, 2021
PubMed

Insights

Abdominal obesity indicators effectively screen for pediatric non-alcoholic fatty liver disease (NAFLD). Trunk fat index (TFI) demonstrated the highest predictive accuracy, aiding early intervention to prevent liver disease progression.

Area of Science:

  • Pediatric Endocrinology
  • Hepatology
  • Obesity Research

Background:

  • Abdominal obesity is a significant risk factor for pediatric non-alcoholic fatty liver disease (NAFLD).
  • Early identification and intervention are crucial for managing NAFLD and preventing liver disease progression.
  • Accurate screening tools are needed to identify at-risk children.

Purpose of the Study:

  • To compare the discriminative performance of six abdominal obesity indicators for screening pediatric NAFLD.
  • To identify the most effective indicator for predicting NAFLD in children.
  • To establish optimal cut-off values for selected indicators.

Main Methods:

  • A cohort of 1350 Chinese children aged 6-8 years was studied.
  • Anthropometric (WC, WHR, WHtR), body composition (TFI, VFA), and endocrine (VAI) indicators were measured.
  • Statistical analyses included Spearman correlation, ROC curves, and logistic regression to assess predictive ability.

Main Results:

  • All six indicators showed robust NAFLD prediction (AUC 0.69-0.96).
  • Trunk fat index (TFI), waist circumference (WC), and visceral fat area (VFA) were the top three predictors.
  • TFI achieved the highest AUC (0.94 for boys, 0.96 for girls) with specific cut-off values.

Conclusions:

  • User-friendly body composition indicators, such as TFI, are effective for identifying pediatric NAFLD.
  • These indicators can facilitate early weight management and help prevent liver disease progression.
  • TFI offers a reliable and interpretable screening tool for clinical practice.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
28
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
236
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.4K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
3.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
35
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
37